|
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Clinical research trials and Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer. Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer  Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
For Condition: recurrent colon cancer,stage 4 colon cancer,recurrent rectal cancer,Stage 4 rectal cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib with oxaliplatin, leucovorin, and fluorouracil in treating patients who have metastaticcolorectal cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose of erlotinib when administered with oxaliplatin, leucovorin calcium, and fluorouracil in patients with metastatic colorectal cancer. - Determine the pharmacokinetics of this regimen in these patients. - Determine any antitumor activity of this regimen in these patients. - Determine the time to progression in patients treated with this regimen. - Determine the objective response rate and response duration in patients treated with this regimen. - Determine the safety and tolerability of this regimen in these patients. OUTLINE: This is a dose-escalation study of erlotinib. - During the first week of the first course only, patients receive oral erlotinib daily alone. Patients then begin the regular schedule comprising oral erlotinib daily, oxaliplatin IV over 2 hours on day 1, and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Treatment repeats every 2 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. - Phase II: Patients receive erlotinib at the MTD plus oxaliplatin, leucovorin calcium, and fluorouracil as in phase I. Erlotinib may be administered alone if toxicity is caused by oxaliplatin, leucovorin calcium, and fluorouracil. Patients are followed for at least 6 months or until disease progression. PROJECTED ACCRUAL: A total of 4-18 patients will be accrued for phase I of this study within 1-4 months. A total of 50 patients will be accrued for phase II of this study within 10 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed colon or rectal cancer - Metastatic or unresectable disease - Unidimensionally measurable disease required for phase II only - At least 20 mm by x-ray, CT scan, MRI, or photography - The following are not considered measurable: - Pleural effusion or ascites - Osteoblastic lesions - Evidence of disease on bone scan alone - Progressive irradiated lesions alone - Bone marrow involvement - Brain metastases - Malignant hepatomegaly by physical exam alone - Chemical markers (e.g., carcinoembryonic antigen) - Recurrent disease after surgery or radiotherapy is considered measurable as long as the following criteria are met: - At least 4 weeks since prior surgery or radiotherapy - Measurable disease exists outside the radiation port or clear progression exists within the radiation port - Tissue accessible for immunohistochemical evidence of epidermal growth factor receptor expression from a metastatic site (phase II only) - No known brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - More than 3 months Hematopoietic - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin normal - AST/ALT no greater than 2.5 times upper limit of normal Renal - Creatinine normal OR - Creatinine clearance at least 60 mL/min Cardiovascular - No unstable angina pectoris - No symptomatic congestive heart failure - No cardiac arrhythmia - No uncontrolled hypertension (systolic blood pressure greater than 150 mm Hg) Opthalmic - No abnormalities of the cornea (e.g., severe dry eye syndrome or Sjogren's syndrome) - No congenital abnormality (e.g., Fuch's dystrophy) - No abnormal slit-lamp examination using vital dye (e.g., fluorescein or Bengal-Rose) - No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear-production test) - Mild dry eye syndrome allowed if patient can use artificial tears and ophthalmologist concurs Gastrointestinal - No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation - No active peptic ulcer disease Other - Must be able and willing to undergo a mediport insertion - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other malignancy within the past 5 years except previously excised and inactive basal cell or squamous cell skin cancer - No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib or other study drugs (e.g., epidermal growth factor inhibitors like cetuximab) - No significant traumatic injury within the past 3 weeks - No peripheral neuropathy grade 2 or greater - No ongoing or active infection - No other uncontrolled concurrent illness that would preclude study entry - No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - Phase I: - Prior chemotherapy allowed - Phase II: - No prior chemotherapy for metastatic disease - Prior adjuvant therapy allowed if disease progresses during adjuvant therapy - No prior oxaliplatin Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics - More than 4 weeks since prior radiotherapy and recovered Surgery - See Disease Characteristics - More than 3 weeks since prior major surgery and recovered - No prior surgical procedures affecting absorption Other - No other concurrent investigational agents - No other concurrent anticancer agents or therapies (commercial or investigational) - No concurrent combination antiretroviral therapy for HIV-positive patients
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LeonardSaltz, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Leonard Saltz 212-639-2501
Additional Information:
Study ID Numbers: CDR0000257808; NCI-5371,MSKCC-02039
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00049101
Other Recurrent Colon Cancer Studies:
1. Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
2. BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
3. Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer
4. Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
5. Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Related Studies:
Other recurrent colon cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
|
|
|
|
|
|
|
|
